Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report highlights advancements in the emu™ Brain Scanner trials, including the activation of additional hospitals for patient recruitment and ongoing studies for the First Responder device. The company reported cash reserves of substantial value and outlined its funding strategies, including grant programs and a recent oversubscribed share purchase plan. Overall, the filing provides insights into EMvision's operational progress and financial health as it continues to develop innovative neurodiagnostic technologies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- Strong emu Clinical Trial & Program Progress
- First Responder Aeromedical Study Commences
- Oversubscribed SPP Raises $2.0M
- Oversubscribed SPP To Close Early
- $3m CRC-P Grant Executed & First Payment Received
Later from EMvision Medical Devices
- Half Yearly Report and Accounts
- EMVision Medical Devices to Present at Australia Investor Day February 26th
- S&P DJI Announces March 2026 Quarterly Rebalance
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- $3.8m R&D Rebate Received & Overseas Finding Approved
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices